Pumactant

Drug Profile

Pumactant

Alternative Names: AdSurf; ALEC; Artificial lung expanding compound; Zofac

Latest Information Update: 04 Aug 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Britannia Pharmaceuticals
  • Class Phospholipids; Pulmonary surfactants
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Market Withdrawal Neonatal respiratory distress syndrome
  • No development reported Post-surgical adhesions
  • Discontinued Asthma; Respiratory tract disorders

Most Recent Events

  • 08 Sep 2009 Discontinued - Phase-II for Asthma in United Kingdom (Inhalation)
  • 08 Sep 2009 Discontinued - Preclinical for Respiratory tract disorders in United Kingdom (unspecified route)
  • 12 Nov 2004 Pumactant has been licensed to airPharma worldwide (except the UK and Ireland) for the treatment of asthma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top